Cutaneous basal cell carcinoma

Hello!  We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.  Please help us by filling it out!  Link: http://j.mp/2BlBaoQ

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Section editor
	Elizabeth Buchbinder, MD Boston, MA LinkedIn

If you're looking for squamous cell carcinoma (SCC) regimens, they've been moved to a separate page.

6 regimens on this page 7 variants on this page

Guidelines

NCCN

• NCCN Guidelines - Basal Cell Skin Cancer

Neoadjuvant chemotherapy

Bleomycin & Cisplatin

back to top

Regimen

Study	Evidence
Denic et al. 1999	Pilot, <20 patients reported

Case reports only.

Chemotherapy

• Cisplatin (Platinol) 20 mg/m² IV once per day on days 1 to 4
• Bleomycin (Blenoxane) 20 mg IV once per day on days 1 to 4

21-day cycle for 3 cycles

References

1. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. link to original article contains protocol PubMed

Advanced or metastatic disease, all lines of therapy

Cisplatin & Doxorubicin

back to top

Regimen

Study	Evidence
Guthrie et al. 1990	Non-randomized

Chemotherapy

• Cisplatin (Platinol) 75 mg/m² IV once on day 1
• Doxorubicin (Adriamycin) 50 mg/m² IV once on day 1

21-day cycles

References

1. Guthrie TH, Porubsky ES. Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope. 1982 Nov;92(11):1298-9. PubMed
2. Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985 Apr 15;55(8):1629-32. PubMed
3. Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. link to original article contains verified protocol PubMed

Cisplatin & Paclitaxel

back to top

Regimen

Study	Evidence
Jefford et al. 2004	Pilot, <20 patients reported

Case report only.

Chemotherapy

• Cisplatin (Platinol) 75 mg/m² IV once on day 1
• Paclitaxel (Taxol) 135 mg/m² IV over 3 hours once on day 1

21-day cycles

References

1. Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004 Aug;74(8):704-5. link to original article contains verified protocol PubMed

Sonidegib monotherapy

back to top

Regimen

Study	Evidence	Comparator
Migden et al. 2015 (BOLT)	Randomized Phase II	Sonidegib 800 mg

In BOLT, 200 mg was assessed as having a better benefit-to-risk profile than the other tested dose, 800 mg.

Chemotherapy

• Sonidegib (Odomzo) 200 mg PO once per day

Given until progression of disease or unacceptable toxicity

References

1. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716-28. link to original article contains verified protocol PubMed

Vismodegib monotherapy

back to top

Regimen

Study	Evidence
Sekulic et al. 2012	Non-randomized

Chemotherapy

• Vismodegib (Erivedge) 150 mg PO once per day

References

1. Phase I: Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. Epub 2009 Sep 2. link to original article contains verified protocol PubMed
2. Phase I: LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2502-11. Epub 2011 Feb 7. link to original article contains verified protocol link to PMC article PubMed
3. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2171-9. link to original article link to PMC article PubMed